Journal of Diabetes and Its Complications
Volume 17, Issue 1 , Pages 1-6 , January 2003

Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus

Received 7 December 2001 ,Revised 27 March 2002 ,Accepted 3 April 2002.

References 

  1. Adler SG, Pahl M, Seldin MF. Deciphering diabetic nephropathy: progress using genetic strategies. Current Opinion in Nephrology and Hypertension. 2000;9:99–106
  2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine. 1994;331:1480–1487
  3. Aillo LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney International. 2000;77:S113–S119
  4. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1993;25:496–501
  5. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Human Immunology. 1999;60:1245–1249
  6. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, et al. Vascular endothelial growth factor mRNA and protein expression in human kidney. Kidney International. 1992;142:1457–1461
  7. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney International. 2000;58(Suppl. 77):S104–S112
  8. Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, et al. Diabetic Medicine. 2000;17:650–656
  9. Chowdhury TA, Kumar S, Barnett AH, Bain SC. Nephropathy in type 1 diabetes: the role of genetic factors. Diabetic Medicine. 1995;12:1059–1067
  10. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48:2229–2239
  11. DCCT . The effect of intensive insulin treatment of diabetes in the development and progression of long-term complications of insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986
  12. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. Journal of the American Society of Nephrology. 2001;12:993–1000
  13. Del Prete D, Angelani F, Ceol M, D'Angelo A, Forino M, Vianello D, et al. Molecular biology of diabetic glomerulosclerosis. Nephrology, Dialysis, Transplantation. 1998;13(Suppl. 8):20–25
  14. Demaine A, Cross D, Millward BA. Polymorphisms of the aldose reductase gene susceptibility to retinopathy in type 1 diabetes mellitus. Investigative Ophthalmology & Visual Science. 2000;41:4064–4068
  15. Doria A, Warram JH, Krolewski AS. Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics. Diabetes Metabolic Review. 1995;11:281–287
  16. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL, et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Laboratory Investigation. 1998;78:1017–1027
  17. Gröne HJ. Angiogenesis and vascular endothelial growth factor (VEGF): is it relevant in renal patients?. Nephrology, Dialysis, Transplantation. 1995;10:761–763
  18. Heesom AE, Hibberd ML, Millward BA, Demaine AG. A polymorphism at the 5′ end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes. 1997;46:287–291
  19. Hodgkinson AD, Sondergaard KL, Yang B, Cross DF, Millward BA, Demaine AG. Aldose reductase expression is induced by hyperglycaemia in diabetic nephropathy. Kidney International. 2001;60:211–218
  20. Hovind P, Tarnow L, Oestergaard PB, Parving HH. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney International. 2000;57(Suppl. 75):S56–S61
  21. Kim NH, Jung HH, Cha DR, Choi DS. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. Journal of Endocrinology. 2000;165:617–624
  22. Lijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney International. 1993;44:959–966
  23. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: identification of a 5′ enhancer. Circulation Research. 1995;77:638–643
  24. Moczulski DK, Scott L, Antonellis A, Rogus JJ, Rich SS, Warram JH, et al. Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in type 1 diabetes mellitus. Diabetic Medicine. 2000;17:111–118
  25. Molitch ME. The relationship between glucose control and the development of diabetic nephropathy in type 1 diabetes. Seminars in Nephrology. 1997;17:101–103
  26. Molyneaux LM, Constantino MI, McGill M, Zilkens R, Yue DK. Better glycaemic control and risk reduction of diabetic complications in type 2 diabetes: comparison with the DCCT. Diabetes Research and Clinical Practice. 1998;42:77–83
  27. Murata T, Ishibashi K, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor play a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Research. 1995;27:48–52
  28. Olmos P, Futers S, Acosta AM, Siegel S, Maiz A, Schiaffino R, et al. (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetes. Diabetes Research and Clinical Practice. 2000;47:169–176
  29. Parving HH, Tarnow L, Rossing P. Genetics of diabetic nephropathy. Journal of the American Society of Nephrology. 1996;7:2509–2517
  30. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial factor is associated with vascular endothelial growth factor plasma levels. Journal of Vascular Research. 2000;37:443–448
  31. Shah VO, Scavini M, Nikolic J, Sun Y, Vai S, Griffith JK, et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. Journal of Clinical Endocrinology and Metabolism. 1998;83:2886–2891
  32. Shweki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–845
  33. Simon E, Gröne HJ, Johren O, Kullmer J, Plate KH, Risau W, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. American Journal of Physiology. 1995;268:240–250
  34. Sone H, Kawakami Y, Lkuda Y, Kondo S, Hanatani M, Suzuki H, et al. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. Biochemical and Biophysical Research Communications. 1996;221:193–198
  35. Steffes MW. Glycemic control and the initiation and progression of the complications of diabetes mellitus. Kidney International, Supplement. 1997;63:S36–S39
  36. Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabetic Medicine. 1995;12:566–579
  37. Tilton RG, Kakahiko T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. Journal of Clinical Investigation. 1997;99:2192–2202
  38. Tiwari JL, Terasaki PI. The data and statistical analysis in HLA and disease associations. In:  Tiwari JL,  Terasaki PI editor. New York: Springer-Verlag; 1985;p. 18–27
  39. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α hypoxia response element VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research. 2000;60:6248–6252
  40. Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–1235
  41. Williams B. Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissue. Diabetologia. 1997;40(Suppl. 2):118–120
  42. Willimson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al. Perspectives in diabetes: hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42:801–813

PII: S1056-8727(02)00181-2

Journal of Diabetes and Its Complications
Volume 17, Issue 1 , Pages 1-6 , January 2003

Article Tools